Clinical trialNCT04655586CompletedPhase 2/PHASE3Interventional

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

SponsorARCA Biopharma, Inc.Enrollment160Covid19

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential antiviral properties, shortens time to recovery compared to heparin in hospitalized patients with COVID-19 and elevated D-dimer levels.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Marc Bonaca, MD, MPH
CPC Clinical Research
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Arca Investigational Site #127
San Nicolás de los Arroyos, Buenos Aires, Argentina
Arca Investigational Site #130
Rosario, Santa Fe Province, Argentina
Arca Investigational Site #112
Rosario, Sante Fe, Argentina
Arca Investigational Site #111
Buenos Aires, Argentina
Arca Investigational Site #115
CABA, Argentina
Arca Investigational Site #126
Córdoba, Argentina
Arca Investigational Site #106
San Miguel de Tucumán, Argentina
Arca Investigational Site #129
San Miguel de Tucumán, Argentina

Brazil

Arca Investigational Site #125
Campo Grande, Mato Grosso do Sul, Brazil
Arca Investigational Site #124
Bragança Paulista, São Paulo, Brazil
Arca Investigational Site #122
São José do Rio Preto, São Paulo, Brazil
Arca Investigational Site #123
Porto Alegre, Brazil
Arca Investigational Site #121
São Paulo, Brazil

United States

Arca Investigational Site #119
Fairhope, Alabama, United States
Arca Investigational Site #118
Phoenix, Arizona, United States
Arca Investigational Site #120
Tucson, Arizona, United States
Arca Investigational Site #104
Aurora, Colorado, United States
Arca Investigational Site #117
Denver, Colorado, United States
Arca Investigational Site #101
Jacksonville, Florida, United States
Arca Investigational Site #128
Evanston, Illinois, United States
Arca Investigational Site #113
New Orleans, Louisiana, United States
Arca Investigational Site #105
Falls Church, Virginia, United States
Arca Investigational Site #114
Richmond, Virginia, United States
Arca Investigational Site #103
Tacoma, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Heparin →RNAPc2

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Dec 2020
Primary completion: 6 Dec 2021
Completion: 7 Mar 2022
Last update posted: 21 Feb 2023
Registered enrollment: 160
Registry id: NCT04655586

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.